This Week in Psychedelics

Connecticut budget funds psychedelic treatment. MindMed sees positive results from phase 2 trials evaluating LSD in anxiety disorders.

May 13, 2022

This Week...

The governor of Connecticut signed a large-scale budget bill that includes provisions to set the state up to provide certain patients with access to psychedelic-assisted treatment using substances like MDMA and psilocybin. Check it out:

MindMed (NASDAQ: MNMD) announced positive top line data from its Phase 2 trial evaluating LSD in anxiety disorders. The data demonstrated the significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression. Here’s more:

More mainstream coverage for psychedelics this week as a story about psychedelics and music therapy was featured in the The Times. Check it out:

Did You Know?

Did you know that in the Bwiti religion, iboga is identified with the Judeo-Christian tree of knowledge?

The Bwiti tradition of Gabon and Cameroon is a syncretic religion incorporating aspects of Christianity. The iboga shrub, a source of the psychedelic substance ibogaine, plays an important role in Bwiti rituals. The Bwiti identify iboga with the tree of the knowledge of good and evil found in Genesis, and iboga is consumed collectively for four days during the Christmas and Easter periods. It is also used for initiation rites—at much higher doses. You can read more about traditional ibogaine use here.